In This Section

Home / Advocate / Letters and Statements

Letters and Statements

ACCC writes and signs on to letters to Congress and the Administration to promote our policy interests. We also write advocacy statements, blog posts, and opinion pieces on a wide range of topics in cancer care. Questions related to health policy? Contact Christian Downs, JD, MHA, President, CMI Association Management.

Follow ACCC (@ACCCBuzz) on Twitter for late-breaking cancer policy news and announcements.

Latest Letters

  • ACCC Signs Letter in Support of the Reducing Hereditary Cancer Act
    March 21, 2023

    ACCC joins a broad coalition of patients, advocacy organizations, cancer centers, and healthcare professionals to express support for the Reducing Hereditary Cancer Act. This crucial piece of legislation would address unacceptable care gaps in Medicare beneficiary access to genetic testing for hereditary cancer risk, evidence-based screening, and risk-reducing interventions, when medically necessary and appropriate.
    Read the Letter

  • ACCC Asks Congress to Improve Access to Genetic Counselors in End-of-Year Package
    November 28, 2022

    ACCC joined more than 250 organizations in asking congressional leadership to include the Access to Genetic Counselor Services Act (S. 1450/H.R. 2144) in an end-of-year legislative package. This piece of legislation would allow the Medicare program to directly reimburse genetic counselors, improving Medicare beneficiary access to comprehensive genetic counseling services.
    Read the Letter

  • ACCC Joins Radiation Oncology Community in Letter to Congress
    November 21, 2022

    In a letter to congressional leadership, ACCC joined the American Society for Radiation Oncology (ASTRO) and more than 20 other organizations asking Congress to pass legislation before the end of the year to prevent significant Medicare payment cuts to radiation therapy services. These cuts largely stem from the 2023 Medicare Physician Fee Schedule, PAYGO sequester, and clinical labor price updates.
    Read the Letter

  • ACCC Sends End-of-Year Legislative Priorities to Congressional Leadership
    October 18, 2022

    ACCC sent a letter to House and Senate leaders this week, encouraging Congress to take action before the end of this year to mitigate significant Medicare payment cuts and improve patient access to high quality, efficient, and equitable cancer care. Without congressional intervention, significant reductions to Medicare payment will take effect in January 2023, including the proposed 4.42% reduction to the Medicare Physician Fee Schedule conversion factor and 4% Statutory Pay-As-You-Go sequester. Additional priorities include supporting the transition to value-based care, extending telehealth flexibilities beyond the COVID-19 public health emergency, and improving prior authorization processes in the Medicare Advantage program.
    Read the Letter

  • ACCC Expresses Concern to FDA Regarding Inspection Delays
    October 11, 2022

    In a letter to U.S. Food and Drug Administration (FDA) Commissioner Robert Califf, M.D., ACCC raises concern about recent delays in inspections of manufacturing facility that have led to interruptions in the approval of breakthrough therapies. We are particularly concerned when these delays impact novel treatments for diseases without FDA-approved therapies available and those that disproportionately impact minority communities.
    Read the Letter

Recent Advocacy News Releases

  • ACCC Applauds Senate Leaders for Introducing Bipartisan Legislation to Expand Medicare Coverage of Early Cancer Screenings

    Jun 30, 2023

    Senators Mike Crapo, Michael Bennet, Tim Scott, and Ben Cardin introduced the Medicare Multi-Cancer Early Detection Screening Coverage Act (S. 2085) last week. This important legislation provides Medicare with the authority to cover the latest innovative cancer screening technologies once they have been approved by the Food and Drug Administration. With these MCED tests, clinicians will be able to screen for dozens of types of cancers at once --- many of which currently have no early detection methods.

  • ACCC Statement on Chemotherapy Drug Shortages

    Jun 14, 2023

    The Association of Community Cancer Centers (ACCC) is highly concerned about the ongoing shortages of platinum-based chemotherapy agents (e.g., cisplatin and carboplatin), two medications that (individually or in combination) treat and cure a wide range of cancers, including but not limited to gastric, pancreatic, colorectal, esophageal, cervical, and ovarian.

  • ACCC Thankful for Inclusion of Key Priorities in Omnibus Package

    Dec 21, 2022

    The Association of Community Cancer Centers (ACCC) is grateful that Congress is poised to address many of our year-end policy priorities in its proposed fiscal year 2023 omnibus appropriations package released this week.

  • ACCC Statement on the Supreme Court Decision in Dobbs v. Jackson Women’s Health

    Jul 14, 2022

    In the wake of the Supreme Court’s recent decision on Dobbs overturning its 1973 ruling on Roe v. Wade, the Association of Community Cancer Centers (ACCC) has become increasingly concerned with the impact this decision may have on patients with cancer and their care teams.